Hormonal
Once-weekly subcutaneous semaglutide at 1.0mg significantly lowers HbA1c and promotes weight loss in patients with Type 2 Diabetes compared to other glucose-lowering therapies.
For patients with Type 2 Diabetes, once-weekly subcutaneous semaglutide at 1.0mg is a highly effective treatment for lowering HbA1c (reducing it by 1.6-1.9%) and promoting weight loss. It is superior to other common glucose-lowering medications and even other GLP-1 RAs like dulaglutide in head-to-head comparisons.
The fall in HbA1c was significantly greater for both doses of semaglutide versus comparator and ranged from 13.2-16.0 mmol/mol (1.2-1.5%) for 0.5mg QW and 16.8-20.2mmol/mol (1.6-1.9%) for semaglutide 1.0mg QW.
Why this rating
Based on Phase 3 RCTs (SUSTAIN 1-5) with 8,416 participants.
Source
Recent developments in <scp>GLP‐1RA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie Bain et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14487
More from this paper
- Once-weekly subcutaneous semaglutide at 2.4mg induces significant weight loss (mean 14.9%) in adults with obesity, significantly outperforming placebo.Strong
- Once-weekly subcutaneous semaglutide at 2.4mg reduces the risk of major adverse cardiovascular events (MACE) in overweight or obese individuals with cardiovascular disease who do not have diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →